drugset / Trial / NCT04861948
IBI188 Combination Therapy in Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase Ib study aim to evaluate the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies
Timeline
- Start
- 2021-05-25
- Primary completion
- 2022-07-30
- Completion
- 2022-07-30
Outcome
Outcome not reported
Stopped: “No signs of efficacy in solid tumors”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI188 | Monoclonal antibody | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | GM-CSF | Protein / enzyme biologic | — | Subcutaneous |
| Background | Pemetrexed | Small molecule | — | Intravenous |
| Background | Sintilimab | Monoclonal antibody | — | Intravenous |